Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25476997 | 1.00 | DPP4 (0.42) | DPP4SRCDPP3MAPK1L3MBTL1 | |
| SCHEMBL21168357 | 0.94 | CYP2C19 (0.43) | DPP4SRCDPP3MAPK1L3MBTL1 | |
| SCHEMBL21168350 | 0.94 | CYP2C19 (0.43) | DPP4SRCDPP3MAPK1L3MBTL1 | |
| SCHEMBL21168348 | 0.94 | CYP2C19 (0.43) | DPP4SRCDPP3MAPK1L3MBTL1 | |
| SCHEMBL25476877 | 0.87 | ACE (0.41) | DPP4 | |
| SCHEMBL25476873 | 0.84 | DPP4 (0.39) | DPP4SRCDPP3MAPK1L3MBTL1 | |
| SCHEMBL25476876 | 0.83 | ACE (0.37) | DPP4SRC | |
| SCHEMBL25476887 | 0.82 | VSIR (0.36) | DPP4SRC | |
| SCHEMBL25476861 | 0.81 | ACE (0.40) | DPP4SRC | |
| SCHEMBL21168325 | 0.80 | ACE (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | DPP4 4748/4885SRC 927/4885DPP3 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.